Table 1 Clinical and Demographic Characteristics stratified by age-of-diagnosis of the RISK cohort

From: Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis

 

VEO CD A1a (0- < 6 years)

EO younger CD (A1a, 6- < 10 years)

EO older CD (A1b,≥10 years)

P-value

P-value

 

N = 36

N = 196

N = 714

VEO A1a vs. EO A1b

EO A1a vs. EO A1b

Mean (SD) Age (years)

4.7 (1)

8.6 (1)

13.5(2)

  

Male gender % (n)

67% (24)

59% (116)

62% (446)

0.51

0.45

Location at diagnosis

Location L1% (n)

19% (7)

16% (32)

22% (155)

0.83

0.12

Location L2 % (n)

31% (11)

24% (46)

23% (168)

0.49

0.98

Location L3 % (n)

50% (18)

60% (118)

55% (391)

0.34

0.2

Perianal involvement (%)

11% (4)

9% (18)

16% (112)

0.96

0.02

PCDAI at diagnosis

< = 10 [inactive, % (n)]

19% (7)

12% (23)

12% (88)

0.32

0.92

11 to 30 [mild, % (n)]

39% (14)

40% (78)

42% (301)

0.92

0.61

>30 [moderate-severe, %,(n)]

42% (15)

48% (95)

46% (325

0.57

0.51

Baseline diagnostic serology

Positive anti-GMCSF (>1. 6 mcg/mL)

22% (8)

38% (75)

50% (342)

0.003

0.016

Positive ASCA IgA (>20 EU/ml)

8% (3)

19% (37)

26% (188)

0.016

0.03

Positive ASCA IgG (>40 EU/ml)

6% (2)

16% (32)

26% (188)

0.005

0.004

Positive anti CBir1 (>25 EU/ml)

56% (20)

39% (76)

36% (257)

0.002

0.53

Positive pANCA (>30 EU/ml)

8% (3)

13% (25)

16% (115)

0.59

0.27

Therapy within 180 days

Neither IM nor anti-TNFα

56% (20)

28% (54)

28% (199)

0.004

0.929

IM

36% (13)

52% (102)

43% (304)

0.444

0.018

Anti-TNFα

3% (1)

13%(26)

19% (139)

0.012

0.46

Both IM & anti-TNFα

6% (2)

7% (14)

10% (72)

0.374

0.213

PCDAI 6 month after diagnosis

N = 33

N = 187

n = 678

  

< = 10 (clinical remission)

45% (15)

60% (113)

69% (465)

0.004

0.054

Complications during follow up

B1 (inflammatory) to B2 (stricturing) within 3 years of F/U

8.3% (3)

4.1% (8)

7.3% (52)

0.33

0.11

B1 (inflammatory) to B3 (penetrating) within 3 years of F/U

0% (0)

0.5% (1)

4.6% (33)

0.67

0.007

  1. VEO very early onset (<6 years), EO early onset (6 to <17years), PCDAI Pediatric Crohn Disease Activity Index at diagnosis prior to treatment, L1 ileal location, L2 colon-only location, L3 ileo-colonic location, IM Immunomodulators, B1 inflammatory behavior, B2 stricturing behavior, B3 penetrating behavior, pANCA perinuclear anti-neutrophil cytoplasmic antibodies, ASCA anti-Saccharomyces cerevisiae antibodies
Back to article page